Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
116 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00665314 | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | completed | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00741325 | Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610). | completed | — | 178 | Genzyme, a Sanofi CompanyINDUSTRY | 0 |
| Feb 11, 2014 |
| clinicaltrials |
| NCT00930098 | A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia | completed | Phase 2 | 74 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Feb 11, 2014 | clinicaltrials |
| NCT00113048 | Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies | terminated | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 5, 2014 | clinicaltrials |
| NCT00125840 | Clofarabine in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 5, 2014 | clinicaltrials |
| NCT00003305 | Aminopterin in Treating Patients With Refractory Leukemia | completed | Phase 2 | 75 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00004025 | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00010309 | Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00308087 | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma(PREMIER) | terminated | Phase 2 | 75 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Dec 27, 2013 | clinicaltrials |
| NCT00185445 | Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL | completed | Phase 2 | 62 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00220311 | A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia | completed | Phase 4 | 10 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Dec 4, 2013 | clinicaltrials |
| NCT00311129 | Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL | completed | Phase 2 | 41 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00344825 | Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL) | completed | — | 300 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00688883 | Fludara (Oral) Phase II Study for Indolent Lymphoma | completed | Phase 2 | 52 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00181597 | Trilostane for Androgen-Independent Prostate Cancer | completed | Phase 2 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 3, 2013 | clinicaltrials |
| NCT00836043 | Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia | terminated | — | 6 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Dec 3, 2013 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials